# Laboratorios Sophia S.A de C.V. clinical trials: 45 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 45 trials with Laboratorios Sophia S.A de C.V. as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Laboratorios Sophia S.A de C.V.: 45 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/laboratorios-sophia-s-a-de-c-v

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 45
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 45, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 24, 2026 | NCT07429474 | Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema | Laboratorios Sophia S.A de C.V. | Phase 1 | Not yet recruiting | Immunogenicity, Anti-drug Antibodies (ADAs) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07429474) |
| December 26, 2025 | NCT07305987 | PRO-232 in Patients Subjected to Cataract Surgery | Laboratorios Sophia S.A de C.V. | Phase 3 | Recruiting | Cataract Extraction | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07305987) |
| March 5, 2025 | NCT06859476 | Evaluation of Manzanilla® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the Eyes | Laboratorios Sophia S.A de C.V. | Phase 4 | Completed | Ophthalmological Agent Toxicity | 167 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859476) |
| April 29, 2024 | NCT06389110 | Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children. | Laboratorios Sophia S.A de C.V. | Phase 3 | Recruiting | Myopia, Myopia, Progressive | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06389110) |
| April 23, 2024 | NCT06379685 | Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. | Laboratorios Sophia S.A de C.V. | Phase 1 | Not yet recruiting | Dry Eye, Dry Eyes Chronic, Dry Eye Syndromes | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06379685) |
| April 19, 2024 | NCT06375343 | Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® | Laboratorios Sophia S.A de C.V. | Phase 1 | Not yet recruiting | Dry Eye Disease, Dry Eye Sensation, Ocular Surface Disease | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06375343) |
| April 18, 2024 | NCT06373653 | Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensation to the Eyes. | Laboratorios Sophia S.A de C.V. | Phase 4 | Withdrawn | Eye Strain, Eye Strain of Both Eyes | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06373653) |
| April 17, 2024 | NCT06370585 | Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF | Laboratorios Sophia S.A de C.V. | Phase 1 | Completed | Dry Eye Disease, Ocular Surface Disease | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06370585) |
| April 12, 2024 | NCT06363292 | Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects | Laboratorios Sophia S.A de C.V. | Phase 1 | Completed | Ophthalmological Agent Toxicity, Bacterial Conjunctivitis | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06363292) |
| April 8, 2024 | NCT06352541 | Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. | Laboratorios Sophia S.A de C.V. | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06352541) |
| August 1, 2022 | NCT05481489 | Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution | Laboratorios Sophia S.A de C.V. | Phase 1 | Withdrawn | Myopia | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05481489) |
| July 22, 2022 | NCT05470881 | Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201 | Laboratorios Sophia S.A de C.V. | Phase 1 | Completed | Myopia | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05470881) |
| July 22, 2022 | NCT05470868 | Safety and Tolerability of PRO-185 | Laboratorios Sophia S.A de C.V. | Phase 1 | Completed | Hyperemia Eye | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05470868) |
| February 1, 2022 | NCT05217680 | Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema | Laboratorios Sophia S.A de C.V. | Phase 3 | Completed | Diabetic Macular Edema | 509 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05217680) |
| January 11, 2021 | NCT04704531 | Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease. | Laboratorios Sophia S.A de C.V. | Phase 2 | Completed | Dry Eye | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04704531) |
| January 11, 2021 | NCT04704518 | Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy | Laboratorios Sophia S.A de C.V. | Phase 4 | Completed | Photorefractive Keratectomy, Corneal De-epithelialization | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04704518) |
| January 11, 2021 | NCT04702802 | Study to Evaluate the Safety of the Viscoelastic Substance PRO-149, Compared to Healon® EndoCoat. | Laboratorios Sophia S.A de C.V. | Not applicable | Completed | Age-related Cataract, Phacoemulsification | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04702802) |
| January 11, 2021 | NCT04702789 | Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. | Laboratorios Sophia S.A de C.V. | Phase 4 | Terminated | Glaucoma, Open-Angle, Ocular Hypertension | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04702789) |
| January 11, 2021 | NCT04702776 | Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. | Laboratorios Sophia S.A de C.V. | Phase 4 | Completed | Dry Eye | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04702776) |
| January 5, 2021 | NCT04693429 | Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ | Laboratorios Sophia S.A de C.V. | Phase 1 | Completed | Safety, Tolerability, Ocular Surface, Ocular Comfort | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04693429) |
| October 2, 2019 | NCT04111965 | Clinical Trial to Compare the Safety and Efficacy of Nanodrop® | Laboratorios Sophia S.A de C.V. | Phase 1/2 | Completed | Dry Eye | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04111965) |
| September 9, 2019 | NCT04081610 | Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution | Laboratorios Sophia S.A de C.V. | Phase 1 | Completed | Dry Eye | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04081610) |
| May 29, 2019 | NCT03966365 | Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® | Laboratorios Sophia S.A de C.V. | Phase 1 | Completed | Glaucoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03966365) |
| May 28, 2019 | NCT03965052 | Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® | Laboratorios Sophia S.A de C.V. | Phase 1 | Completed | Glaucoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03965052) |
| October 5, 2018 | NCT03698045 | Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers. | Laboratorios Sophia S.A de C.V. | Phase 1 | Withdrawn | Conjunctivitis, Bacterial | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03698045) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 20 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 3 | 10 |
| Phase 4 | 7 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 31 |
| Withdrawn | 5 |
| Terminated | 4 |
| Not yet recruiting | 3 |
| Recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dry Eye Syndromes | 13 |
| Conjunctivitis, Bacterial | 5 |
| Glaucoma, Open-Angle | 5 |
| Glaucoma | 5 |
| Ocular Hypertension | 4 |
| Myopia | 3 |
| Cataract | 3 |
| Conjunctivitis, Allergic | 2 |
| Conjunctivitis | 1 |
| Myopia, Degenerative | 1 |
| Asthenopia | 1 |
| Inflammation | 1 |
| Pterygium | 1 |
| Eye Pain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Shipping and delivery companies in the United States](https://specstream.ai/data/businesses/shipping-and-delivery-companies/united-states)
- [Infectious disease clinics in the United States](https://specstream.ai/data/businesses/infectious-disease-clinics/united-states)
- [Cambodian restaurants in the United States](https://specstream.ai/data/businesses/cambodian-restaurants/united-states)
- [Specialty schools in the United States](https://specstream.ai/data/businesses/specialty-schools/united-states)
- [IT consultants in the United States](https://specstream.ai/data/businesses/it-consultants/united-states)
